A



B

Treatment	SUCRA	PrBest	Mean rank
GLP-1RA	89.0	18.9	2.4
Met+GLP-1RA	88.5	38.9	2.5
Met+SGLT2i	71.1	37.6	4.8
DPP4i+SGLT2i	68.8	1.7	5.1
Met+DPP4i	64.6	0.2	5.6
SGLT2i	62.7	0.9	5.9
Met+TZD	57.9	1.5	6.5
Met	55.6	0.0	6.8
Placebo	50.4	0.0	7.4
Met+SU	30.5	0.3	10.0
DPP4i	29.0	0.0	10.2
SU	18.6	0.0	11.6
DPP4i+TZD	10.1	0.0	12.7
TZD	3.0	0.0	13.6

Supplementary Fig. 4. Network geometry (A), rank test (B), the results of network and pairwise meta-analysis (C) for effect on body weight of antidiabetic treatments after 6 months. (A) Each circle represents an antidiabetic treatment that was included in the analysis, with the size of the circle proportional to the number of trials involving the treatment. The width of each connecting line is proportional to the number of subjects who participated in each pair of trials. The global test for inconsistency yielded a *P* value of 0.1806, indicating no evidence of inconsistency in the network. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for effect on body weight (kg) of antidiabetic treatments after 6 months. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in reverse order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonylurea. [a]Results indicate statistical significance.

(*Continued to the next page*)

Supplementary Fig. 4. Continued

C

	TZD	DPP4i+ TZD	SU	DPP4i	Met+SU	Placebo	Met	Met+ TZD	SGLT2i	Met+ DPP4i	DPP4i+ SGLT2i	Met+ SGLT2i	Met+ GLP-1RA	GLP-1RA
TZD	TZD	−0.75 (−3.17 to 1.67)	−1.59 (−3.24 to 0.06)	−2.37[a] (−3.87 to −0.87)	−2.30 (−4.96 to 0.35)	−3.34[a] (−4.89 to −1.79)	−0.23 (−1.66 to 1.21)	−3.57[a] (−5.67 to −1.47)	−3.77[a] (−5.68 to −1.86)	−3.80[a] (−5.20 to −2.41)	−3.97[a] (−5.88 to −2.06)	−4.80 (−10.44 to 0.84)	−5.50[a] (−8.13 to −2.87)	−3.50[a] (−4.60 to −2.40)
DPP4i+ TZD	1.22[a] (0.02 to 2.42) I^2=0.0% 1 study	DPP4i+ TZD	−0.84 (−3.31 to 1.63)	−1.62 (−3.51 to 0.27)	−1.55 (−4.79 to 1.68)	−2.59[a] (−4.78 to −0.40)	−0.07 (−1.57 to 1.43)	−2.82[a] (−5.62 to −0.02)	−3.02[a] (−5.26 to −0.78)	−3.05[a] (−5.37 to −0.74)	−3.22[a] (−5.46 to −0.98)	−4.05 (−9.98 to 1.88)	−4.75[a] (−7.96 to −1.54)	−2.75[a] (−5.13 to −0.37)
SU	0.32 (−0.78 to 1.41) I^2=0.0% 3 studies		SU	−0.78 (−2.37 to 0.81)	−0.71 (−3.42 to 2.00)	−1.75[a] (−3.39 to −0.11)	1.62 (0.02 to 3.21)	−1.98 (−4.15 to 0.19)	−2.18[a] (−4.17 to −0.19)	−2.21[a] (−3.71 to −0.72)	−2.38[a] (−4.36 to −0.39)	−3.21 (−8.87 to 2.45)	−3.91[a] (−6.59 to −1.23)	−1.91[a] (−3.50 to −0.32)
DPP4i	2.40[a] (1.66 to 3.15) I^2=0.0% 2 studies	1.62 (−0.08 to 3.32) I^2=0.0% 1 study		DPP4i	0.07 (−2.55 to 2.69)	−0.97 (−2.06 to 0.12)	−1.20 (−3.62 to 1.22)	−1.20 (−3.26 to 0.86)	−1.40[a] (−2.59 to −0.21)	−1.43[a] (−2.76 to −0.10)	−1.60[a] (−2.79 to −0.41)	−2.43 (−8.05 to 3.19)	−3.13[a] (−5.72 to −0.54)	−1.13 (−2.56 to 0.30)
Met+SU					Met+SU	−1.04 (−3.69 to 1.61)	0.07 (−1.72 to 1.86)	−1.27 (−4.28 to 1.74)	−1.47 (−4.35 to 1.41)	−1.50 (−3.76 to 0.76)	−1.67 (−4.55 to 1.21)	−2.50 (−7.47 to 2.47)	−3.20 (−6.59 to 0.20)	−1.20 (−3.82 to 1.42)
Placebo	0.50 (−4.64 to 5.64) I^2=0.0% 1 study			0.34[a] (0.09 to 0.60) I^2=52.5% 11 studies		Placebo	0.47 (−1.09 to 2.03)	−0.23 (−2.32 to 1.86)	−0.43 (−2.05 to 1.19)	−0.46 (−1.85 to 0.92)	−0.63 (−2.25 to 0.99)	−1.46 (−7.10 to 4.17)	−2.16 (−4.78 to 0.46)	−0.16 (−1.65 to 1.33)
Met	1.82[a] (1.60 to 2.05) I^2=81.0% 6 studies		2.13[a] (1.42 to 2.84) I^2=0.0% 4 studies	1.13[a] (0.86 to 1.39) I^2=0.0% 4 studies		0.22 (−0.46 to 0.90) I^2=30.8% 3 studies	Met	−1.30 (−6.83 to 4.23)	2.75 (0.60 to 4.90)	0.43 (−0.89 to 1.75)	−0.06 (−1.29 to 1.16)	−2.00 (−4.38 to 0.38)	−0.30 (−1.16 to 0.55)	1.13[a] (0.11 to 2.15)
Met+TZD							−0.07 (−1.65 to 1.51) I^2=0.0% 1 study	Met+TZD	−0.20 (−2.58 to 2.18)	−0.23 (−2.22 to 1.75)	−0.40 (−2.78 to 1.98)	−1.23 (−7.04 to 4.58)	−1.93 (−4.91 to 1.05)	0.07 (−1.99 to 2.13)
SGLT2i				2.37[a] (1.96 to 2.79) I^2=71.5% 3 studies		2.08[a] (1.81 to 2.34) I^2=21.2% 6 studies			SGLT2i	−0.03 (−1.82 to 1.75)	−0.20 (−1.28 to 0.88)	−1.03 (−6.78 to 4.72)	−1.73 (−4.58 to 1.12)	0.27 (−1.59 to 2.13)
Met+ DPP4i				1.00[a] (0.45 to 1.56) I^2=0.0% 1 study	1.50 (−0.60 to 3.60) I^2=0.0% 1 study	0.03 (−0.65 to 0.71) I^2=0.0% 1 study	0.19 (−0.16 to 0.55) I^2=40.7% 3 studies			Met+DPP4i	−0.17 (−1.95 to 1.62)	−1.00 (−6.46 to 4.46)	−1.70 (−4.23 to 0.83)	0.30 (−1.02 to 1.63)
DPP4i+ SGLT2i				1.60[a] (0.76 to 2.44) I^2=0.0% 1 study					0.20 (−0.48 to 0.88) I^2=0.0% 1 study		DPP4i+ SGLT2i	−0.83 (−6.58 to 4.91)	−1.53 (−4.38 to 1.32)	0.47 (−1.39 to 2.33)
Met+ SGLT2i					2.50 (−2.40 to 7.40) I^2=0.0% 1 study							Met+ SGLT2i	−0.70 (−6.72 to 5.32)	1.30 (−4.32 to 6.92)
Met+ GLP-1RA							2.00 (−0.23 to 4.23) I^2=0.0% 1 study						Met+ GLP-1RA	2.00 (−0.59 to 4.59)
GLP-1RA	3.50[a] (2.79 to 4.21) I^2=0.0% 1 study		1.99[a] (1.53 to 2.45) I^2=0.0% 1 study	1.20[a] (0.50 to 1.90) I^2=0.0% 1 study		1.71[a] (1.33 to 2.08) I^2=68.2% 4 studies	0.16 (−0.56 to 0.24) I^2=50.3% 3 studies							GLP-1RA